10 Takeover Targets to Watch This Fall

10 Takeover Targets to Watch This Fall

5 questions ESMO cancer drug data might answer

5 questions ESMO cancer drug data might answer

All the ASCO skinny: Lynparza’s pancreatic win, Amgen’s KRAS spotlight, Merck’s history-busting and more

All the ASCO skinny: Lynparza's pancreatic win, Amgen's KRAS spotlight, Merck's history-busting and more

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use in Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use in Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials

Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials

10 Takeover Targets to Watch in 2019

0 Takeover Targets to Watch in 2019